Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

Brief description of study

The purpose of this study is to compare the safety and effectiveness of the study product, CSB-001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Neurotrophic Keratitis
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older Subjects with stage 2 (PED) or stage 3 (corneal ulcer) NK

Updated on 09 Mar 2024. Study ID: 849886

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).